The first one to show effect in lymphoma was 10058-F4, which was employed in vitro in different BL cell lines and demonstrated that targeting of MYC/MAX interaction could impair lymphoma growth in a time- and dose-dependent manner[96]. Here, MAX is linked to lymphoma.